GRADE, Grading of Recommendations Assessment Development and Evaluation

等级,建议评估开发和评估的分级
  • 文章类型: Journal Article
    急性肝衰竭(ALF)是罕见的,不可预测的,各种病因导致的急性肝损伤(ALI)的潜在致命并发症。文献中报道的ALF病因具有区域差异,影响临床表现和自然病程。在旨在反映印度临床实践的共识文章的这一部分中,疾病负担,流行病学,临床表现,监测,和预测已经讨论过了。在印度,病毒性肝炎是ALF的最常见原因,抗结核药物引起的药物性肝炎是第二常见的原因。ALF的临床表现以黄疸为特征,凝血病,和脑病。区分ALF和其他肝衰竭的原因是很重要的,包括慢性急性肝衰竭,亚急性肝功能衰竭,以及某些可以模仿这种表现的热带感染。该疾病通常具有暴发性临床过程,短期死亡率很高。死亡通常归因于脑部并发症,感染,导致多器官衰竭。及时肝移植(LT)可以改变结果,因此,在可以安排LT之前,为患者提供重症监护至关重要。评估预后以选择适合LT的患者同样重要。已经提出了几个预后评分,他们的比较表明,本土开发的动态分数比西方世界描述的分数更具优势。ALF的管理将在本文件的第2部分中描述。
    Acute liver failure (ALF) is an infrequent, unpredictable, potentially fatal complication of acute liver injury (ALI) consequent to varied etiologies. Etiologies of ALF as reported in the literature have regional differences, which affects the clinical presentation and natural course. In this part of the consensus article designed to reflect the clinical practices in India, disease burden, epidemiology, clinical presentation, monitoring, and prognostication have been discussed. In India, viral hepatitis is the most frequent cause of ALF, with drug-induced hepatitis due to antituberculosis drugs being the second most frequent cause. The clinical presentation of ALF is characterized by jaundice, coagulopathy, and encephalopathy. It is important to differentiate ALF from other causes of liver failure, including acute on chronic liver failure, subacute liver failure, as well as certain tropical infections which can mimic this presentation. The disease often has a fulminant clinical course with high short-term mortality. Death is usually attributable to cerebral complications, infections, and resultant multiorgan failure. Timely liver transplantation (LT) can change the outcome, and hence, it is vital to provide intensive care to patients until LT can be arranged. It is equally important to assess prognosis to select patients who are suitable for LT. Several prognostic scores have been proposed, and their comparisons show that indigenously developed dynamic scores have an edge over scores described from the Western world. Management of ALF will be described in part 2 of this document.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    肝细胞癌(HCC)是其发病的主要原因之一。死亡率,以及印度慢性肝病患者的医疗支出。印度全国肝脏研究协会(INASL)于2014年发布了有关HCC诊断和管理的第一份指南(PuriRecommendations),这些指南在印度和邻国的HCC诊断和管理中受到医疗保健界的好评。然而,自2014年以来,HCC诊断和管理领域出现了许多新的发展,因此,INASL努力更新其2014年共识指南。成立了一个新的HCC工作队,审查了以前的准则以及需要纳入新准则的HCC各个方面的最新发展。为期2天的圆桌讨论于2018年5月5日和6日在普里举行,奥里萨邦,讨论,辩论,并完成修订后的协商一致声明。指南的每个陈述都根据建议评估开发和评估系统的分级进行了分级,并进行了少量修改。我们在这里介绍2019年INASL预防共识更新,诊断,印度肝细胞癌的治疗:Puri-2建议。
    Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management of HCC in India and neighboring countries. However, since 2014, many new developments have taken place in the field of HCC diagnosis and management, hence INASL endeavored to update its 2014 consensus guidelines. A new Task Force on HCC was constituted that reviewed the previous guidelines as well as the recent developments in various aspects of HCC that needed to be incorporated in the new guidelines. A 2-day round table discussion was held on 5th and 6th May 2018 at Puri, Odisha, to discuss, debate, and finalize the revised consensus statements. Each statement of the guideline was graded according to the Grading of Recommendations Assessment Development and Evaluation system with minor modifications. We present here the 2019 Update of INASL Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri-2 Recommendations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    怀孕期间发生的肝脏疾病可能很严重,进展迅速,影响母亲和胎儿的结局。它们是产科医生关注的常见原因,也是转诊给肝病医生的重要原因,胃肠病学家,或医生。怀孕期间的肝脏疾病可以分为妊娠特有的疾病,那些与怀孕巧合的人,和先前存在的肝脏疾病因怀孕而加剧。需要与妊娠相关或无关的肝脏疾病之间的快速鉴别诊断,以便可以对这些疾病进行专科和紧急处理。缺乏专门的印度指南来管理这些患者。印度全国肝脏研究协会(INASL)与印度妇产科协会联合会(FOGSI)联合成立了一个工作组,以制定妊娠期肝病患者管理的共识指南,与印度有关。为了制定这些准则,为期两天的圆桌会议于2018年5月26日至27日在新德里举行,讨论,辩论,并最终确定共识声明。只有工作组大多数成员一致批准的声明才被接受。本综述的主要目的是提出INASL和FOGSI联合批准的诊断和管理肝病孕妇的共识声明。本文概述了妊娠期发生的肝脏疾病,关于其发病机制的关键机制的更新,以及推荐的治疗方案。
    Liver diseases occurring during pregnancy can be serious and can progress rapidly, affecting outcomes for both the mother and fetus. They are a common cause of concern to an obstetrician and an important reason for referral to a hepatologist, gastroenterologist, or physician. Liver diseases during pregnancy can be divided into disorders unique to pregnancy, those coincidental with pregnancy, and preexisting liver diseases exacerbated by pregnancy. A rapid differential diagnosis between liver diseases related or unrelated to pregnancy is required so that specialist and urgent management of these conditions can be carried out. Specific Indian guidelines for the management of these patients are lacking. The Indian National Association for the Study of the Liver (INASL) in association with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) had set up a taskforce for development of consensus guidelines for management of patients with liver diseases during pregnancy, relevant to India. For development of these guidelines, a two-day roundtable meeting was held on 26-27 May 2018 in New Delhi, to discuss, debate, and finalize the consensus statements. Only those statements that were unanimously approved by most members of the taskforce were accepted. The primary objective of this review is to present the consensus statements approved jointly by the INASL and FOGSI for diagnosing and managing pregnant women with liver diseases. This article provides an overview of liver diseases occurring in pregnancy, an update on the key mechanisms involved in its pathogenesis, and the recommended treatment options.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号